Protyon develops molecular modeling tools that create three-dimensional digital representations of cancer mutations, enabling precise predictions of drug interactions and treatment efficacy. This technology allows clinicians to select the most effective therapies for individual patients, improving treatment outcomes and reducing the costs associated with ineffective treatments.
Funding
$640K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NNFounders
Product
Problem
Selecting the most effective cancer treatment for individual patients is challenging due to the unique genetic mutations driving each case. Traditional methods often lack the precision to predict drug interactions with these mutations, leading to ineffective treatments and increased healthcare costs.
Solution
Protyon offers molecular modeling tools that generate three-dimensional digital representations of cancer mutations. By creating these models from a patient's genetic code, Protyon enables detailed insights into how different drugs interact with the tumor at a molecular level. This allows clinicians to predict the effectiveness of available targeted therapies, facilitating the selection of the most appropriate treatment for each patient. The knowledge-based approach supports medication selection for previously unreported mutations, potentially increasing patient life expectancy and reducing the burden on healthcare systems by eliminating ineffective treatments.
Target Audience
Protyon's primary customers are clinicians and life science organizations involved in cancer treatment and research, particularly those focused on precision medicine and targeted therapies.
Features
- Generates 3D digital models of cancer mutations from genetic code.
- Predicts drug interactions with tumor mutations at a molecular level.
- Supports selection of medication for previously unreported mutations.
- Provides insights to enhance the efficiency and precision of research and development in precision medicine.
- Offers a training course for clinicians on using molecular modeling in clinical drug treatment for cancer patients.